Skip to content
value.today

Crescendo Bioscience, Inc.

Total raised
$97 M
3 rounds on record
Latest round
$28 M
Dec 2012
First round on record
Jun 2008
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Crescendo Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2012$28 MNo. 3$10 to $50 million

Crescendo Bioscience, Inc.: Raise no. 3, Dec 2012

Investors in this round

9 investors had bought by the notice of Jan 2, 2013: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Sale and issuance of (i) Series D Preferred Stock, (ii) Warrants, (iii) Series D Preferred Stock underlying Warrants and (iv) Common Stock issuable upon conversion of Series D Preferred Stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,179,400
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Timothy G. Henn · Executive Officer
  • William A. Hagstrom · Executive Officer, Director
  • Brook G. Byers · Director
  • Gary G. Kurtzman · Director
  • George G. Rehm · Director
  • Jack G. Oliver · Director
  • Josh G. Green · Director
  • Larry G. Leisure · Director
  • Leon G. Chen · Director
  • Ralph G. Snyderman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • William J. Kridel (CRD 704171) · broker-dealer FERGHANA SECURITIES, INC. (CRD 43430) · New York, New YorkSold in all US states, and outside the US
  • A. Rawle Michelson (CRD 1507251) · broker-dealer FERGHANA SECURITIES, INC. (CRD 43430) · New York, New YorkSold in all US states, and outside the US
  • E. Hunterson Herie (CRD 2431896) · broker-dealer FERGHANA SECURITIES, INC. (CRD 43430) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “The finders' fees contain $940,000 cash plus warrants”
  • On the amounts: “Total Offering and Sales Amounts assume the exercise of warrants ($454,396.01)”

Signed by Timothy G. Henn, Secretary. Source: SEC Form D, newest notice filed Jan 2, 2013. Read the notice at the SEC.

equity, optionsSEC
Sep 2011$25 MIssued in a merger or acquisition$10 to $50 million

Crescendo Bioscience, Inc.: Private sale, Sep 2011

Investors in this round

1 investor had bought by the notice of Sep 20, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • William A. Hagstrom · Executive Officer, Director
  • William R. Salisbury · Executive Officer
  • Brook R. Byers · Director
  • George R. Rehm · Director
  • Jack R. Oliver · Director
  • Larry R. Leisure · Director
  • Ralph R. Snyderman · Director
  • Sue R. Siegel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William R. Salisbury, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 20, 2011. Read the notice at the SEC.

equity, debtSEC
Jun 2011$31 MNo. 2$10 to $50 million

Crescendo Bioscience, Inc.: Raise no. 2, Jun 2011

Investors in this round

10 investors had bought by the notice of Jun 20, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $40 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series C Preferred Stock and the underlying Common Stock issuable upon conversion thereof.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • William A. Hagstrom · Executive Officer, Director
  • William R. Salisbury · Executive Officer
  • Brook R. Byers · Director
  • George R. Rehm · Director
  • Jack R. Oliver · Director
  • Larry R. Leisure · Director
  • Ralph R. Snyderman · Director
  • Sue R. Siegel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William R. Salisbury, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 20, 2011. Read the notice at the SEC.

equitySEC
Jun 2008$38 MNo. 1$10 to $50 million

Crescendo Bioscience, Inc.: Raise no. 1, Jun 2008

Investors in this round

4 investors had bought by the notice of Jul 7, 2010: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $43 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series B Preferred Stock and the underlying Common Stock issuable upon conversion thereof.
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amy R. Paye · Executive Officer
  • William A. Hagstrom · Executive Officer, Director
  • William R. Salisbury · Executive Officer
  • Brook R. Byers · Director
  • Jack R. Oliver · Director
  • Larry R. Leisure · Director
  • Sue R. Siegel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “This estimate excludes amounts paid and that may be paid to the law firms with which one of the executive officers was or is affiliated.”

Signed by William R. Salisbury, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Jul 7, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Crescendo Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2013).

    SEC Form D · Jan 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2013

That is all the official record says: Crescendo Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Crescendo Bioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Crescendo Bioscience, Inc.
NameRoleNamed in
Timothy G. HennExecutive officerJan 2013
William A. HagstromExecutive officerJan 2013
William R. SalisburyExecutive officerSep 2011
Amy R. PayeExecutive officerJul 2010
Brook G. ByersDirectorJan 2013
Gary G. KurtzmanDirectorJan 2013
George G. RehmDirectorJan 2013
Jack G. OliverDirectorJan 2013
Josh G. GreenDirectorJan 2013
Larry G. LeisureDirectorJan 2013
Leon G. ChenDirectorJan 2013
Ralph G. SnydermanDirectorJan 2013
William A. HagstromDirectorJan 2013
Brook R. ByersDirectorSep 2011
George R. RehmDirectorSep 2011
Jack R. OliverDirectorSep 2011
Larry R. LeisureDirectorSep 2011
Ralph R. SnydermanDirectorSep 2011
Sue R. SiegelDirectorSep 2011
Michael R. GoldbergDirectorDec 2009